|
Peter Hughes, PhD, Fund Manager, Healthcare Strategies at AXA IM, gives his view on the current trials to develop vaccines and treatments for COVID-19, and what the challenges – and next steps – might be.
How close are we to a vaccine for COVID-19 and what are the challenges?
The first potential vaccine for COVID-19, called mRNA-1273, has started human clinical trials. This is a crucial step in drug development and means that healthy volunteers will test the vaccine’s safety before it is tested in a larger group of people. The speed at which this has taken place is remarkable. Usually, getting a potential vaccine through all stages of development to start human trials takes years. However, mRNA-1273 – developed by Moderna Therapeutics...
|